- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04012333
The Effect of Higher Protein Dosing in Critically Ill Patients: A Multicenter Randomized Trial (EFFORTcombo)
Study Overview
Status
Intervention / Treatment
Detailed Description
Positive, neutral, or negative, the results of the EFFORTcombo study will inform the clinical practice in ICU settings around the world. If positive, because of the pragmatic, multicentre nature of this trial, results will be broadly applicable to all critically ill patients worldwide. If the results are negative, it will be ensured that patients no longer receive high-dose protein/amino acid admixtures or possibly, combined EN/PN.
As it relates to critical care nutrition practice in general, there is a long history of practice-changing initiatives. A process of synthesizing (in the form of evidence-based clinical practice guidelines) and disseminating best practice ideas (in the form of web-based repository of tools and information [see www.criticalcarenutrition.com]) was established.
Over the past several years, this program of research with leaders of the American Society of Parenteral and Enteral Nutrition (ASPEN) and this specific protocol at the annual Clinical Nutrition Week with society leaders, researchers, and the clinical nutrition community at large has been discussed. Partnership with ASPEN will further facilitate both, recruitment initiatives and, importantly, the knowledge translation initiatives. These efforts will increase the likelihood of the uptake of EFFORT results across the world.
This study has both the potential to answer a high-priority clinical question and also transform the new approach in clinical nutrition research. It further represents a unique collaboration between ASPEN, its global partners, and the Clinical Evaluation Research Unit, a methodological support center based in Kingston, Ontario, Canada and managed by Dr. Daren Heyland. If successful, this type of collaboration sets an important precedent for how this community may approach additional research questions related to clinical nutrition. Nested within this larger volunteer-driven registry trial, the aim is to complete a significant sub-study that will establish the role of combined EN/PN in these nutritionally high-risk patients. This protocol pertains to the specifics of this sub-study of combined EN/PN. At the end of the trial, the data from this sub-study will be merged into the results of the overall parent EFFORT Trial (where data points are similar).
Study Type
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
NRW
-
Aachen, NRW, Germany, 52074
- University Hospital RWTH Aachen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ≥18 years old;
- Expected to remain mechanically ventilated for an additional 48 hours from screening;
And have one or more of the following risk factors that make them at high nutritional risk:
- Low (≤25) or High BMI (≥35)
- Moderate to severe malnutrition (as defined by local assessments). We will document the means by which sites are making this determination and capture the elements of the assessment (history of weight loss, history of reduced oral intake, etc.).
- Frailty (Clinical Frailty Scale 5 or more from proxy)
- Sarcopenia (SARC-F score of 4 or more from proxy)
- From point of screening, projected duration of mechanical ventilation >4 days
Exclusion Criteria:
- >96 continuous hours of mechanical ventilation before enrollment
- Expected death or withdrawal of life-sustaining treatments within 7 days from screening
- Pregnancy
- The responsible clinician feels that the patient either needs low or high protein
- Absolute contraindication to EN
- Severe metabolic disorders including electrolyte disorders, uncontrolled hyperglycemia, hyperlipidemia, hypophosphatemia.
- Severe chronic liver disease (MELD-score >20) or acute fulminant hepatitis.
- Metabolic disorders involving impaired nitrogen utilization
- Not ambulating independently prior to illness that lead to ICU admission (use of gait aid permitted)
- Lower extremity injury or impairments that prevents them walking prior to hospital discharge (e.g. amputation, knee/hip injury)
- Pre-existing cognitive impairment or language barrier that prohibits outcomes assessment
- Pre-existing primary severe systemic neuromuscular disease resulting in severe weakness pre-ICU (e.g., Guillain Barre)
- Intracranial or spinal process affecting motor function
- Patients in hospital >5 days prior to ICU admission
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Patients will receive standard care plus OLIMEL 7,6%E or if no central venous access available PeriOLIMEL 2,5%E to reach protein targets: >2.2g/kg/day
|
OLIMEL 7,6%E will be administered via a central access whereas PeriOLIMEL 2,5%E will be administered peripherally.
|
No Intervention: Standard Care
Patients will receive standard care (enteral nutrition only) to stay below the protein level: <1.2g/kg/day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
6-minute walking distance
Time Frame: at hospital discharge, up to 12 weeks
|
measured by performing a 6-minute walking test
|
at hospital discharge, up to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall strength-upper and lower extremity
Time Frame: at hospital discharge, up to 12 weeks
|
MRC sum-score
|
at hospital discharge, up to 12 weeks
|
Quadriceps force-lower extremity strength
Time Frame: ICU and at hospital discharge, up to 12 weeks
|
Hand held dynamometry
|
ICU and at hospital discharge, up to 12 weeks
|
Distal strength-hand grip strength
Time Frame: ICU and at hospital discharge, up to 12 weeks
|
Hand grip dynamometry
|
ICU and at hospital discharge, up to 12 weeks
|
Overall Physical Functional status
Time Frame: Baseline (questionnaire only) and SPPB & FSS- ICU at ICU and at hospital discharge, up to 12 weeks
|
Walking Impairment Questionnaire
|
Baseline (questionnaire only) and SPPB & FSS- ICU at ICU and at hospital discharge, up to 12 weeks
|
Overall Physical Functional status
Time Frame: Baseline (questionnaire only) and SPPB & FSS- ICU at ICU and at hospital discharge, up to 12 weeks
|
FSS-ICU
|
Baseline (questionnaire only) and SPPB & FSS- ICU at ICU and at hospital discharge, up to 12 weeks
|
Overall Physical Functional status
Time Frame: Baseline (questionnaire only) and SPPB & FSS- ICU at ICU and at hospital discharge, up to 12 weeks
|
SPPB
|
Baseline (questionnaire only) and SPPB & FSS- ICU at ICU and at hospital discharge, up to 12 weeks
|
Discharge location
Time Frame: at hospital discharge, up to 12 weeks
|
Discharge location
|
at hospital discharge, up to 12 weeks
|
Body composition
Time Frame: Enrollment, ICU day 10 and at hospital discharge, up to 12 weeks
|
Ultrasound of quadriceps
|
Enrollment, ICU day 10 and at hospital discharge, up to 12 weeks
|
Body composition (when clinically available)
Time Frame: Only when clinically available, from 2 weeks before enrolment until 2 weeks after enrolment
|
Abdominal CT scan at 3rd lumbar vertebra
|
Only when clinically available, from 2 weeks before enrolment until 2 weeks after enrolment
|
Health-related quality of life
Time Frame: (Telephone) survey at baseline and 6 months
|
SF-36
|
(Telephone) survey at baseline and 6 months
|
Physical functioning
Time Frame: (Telephone) survey at hospital discharge, up to 12 weeks and 6 months
|
Katz ADL
|
(Telephone) survey at hospital discharge, up to 12 weeks and 6 months
|
Health-related quality of life
Time Frame: (Telephone) survey at 6 months
|
EQ-5D-5L
|
(Telephone) survey at 6 months
|
Physical functioning
Time Frame: (Telephone) survey at 6 months
|
Lawton IADL
|
(Telephone) survey at 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christian Stoppe, MD, University Hospital RWTH Aachen
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-108
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Critical Illness
-
Duke UniversityNational Institute of Neurological Disorders and Stroke (NINDS); National Institutes...CompletedNeonatal Critical Illness | Pediatric Critical IllnessUnited States
-
Yale UniversityNational Institute on Aging (NIA)RecruitingCritical Illness | Illness, CriticalUnited States
-
McMaster UniversityLondon Health Sciences Centre; McMaster Children's Hospital; Canadian Critical...CompletedPediatric Critical IllnessCanada
-
Boston Children's HospitalCompleted
-
St Helens & Knowsley Teaching Hospitals NHS TrustManchester University NHS Foundation TrustCompleted
-
Sándor BeniczkyUniversity of Aarhus; Danish Council for Independent Research; Søster og Verner...CompletedCritical Illness Myopathy | Myopathy Critical IllnessDenmark
-
Hospital de Clinicas de Porto AlegreUnknownCritical Illness PolyneuropathiesBrazil
-
Peking Union Medical College HospitalBaxter Healthcare CorporationUnknownNutrition Therapy for Critical Illness
-
Assistance Publique - Hôpitaux de ParisRecruitingCritical Illness Related Corticosteroids InsufficiencyFrance
-
Yuzuncu Yıl UniversityKahramanmaras Sutcu Imam University; Izmir Ataturk Training and Research HospitalCompleted
Clinical Trials on OLIMEL 7,6%E / PeriOLIMEL 2,5%E
-
Clinical Evaluation Research Unit at Kingston General...Baxter Healthcare CorporationTerminatedCritical Illness | Acute Respiratory FailureUnited States, Canada, Belgium, France
-
University of AlbertaBaxter Healthcare CorporationRecruitingMalnutrition | SurgeryCanada
-
Lawson Health Research InstituteAcademic Medical Organization of Southwestern OntarioCompleted
-
OHSU Knight Cancer InstituteGenentech, Inc.; Oregon Health and Science University; Servier Pharmaceuticals...RecruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8United States
-
Children's Oncology GroupRecruitingLymphoblastic Lymphoma | B Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | T Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia | B Acute Lymphoblastic Leukemia, BCR-ABL1-LikeUnited States, Canada
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingRecurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent B Lymphoblastic Lymphoma | Refractory B Lymphoblastic LymphomaUnited States, Puerto Rico
-
Children's Oncology GroupRecruitingRecurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | Refractory Mixed Phenotype Acute Leukemia | Refractory Acute Leukemia of Ambiguous Lineage | Recurrent Acute Leukemia of Ambiguous Lineage | Recurrent Acute Myeloid Leukemia... and other conditionsUnited States
-
National Cancer Institute (NCI)Not yet recruitingT Acute Lymphoblastic Leukemia | T Lymphoblastic Lymphoma
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedAcute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Childhood B Acute Lymphoblastic LeukemiaUnited States
-
National Cancer Institute (NCI)Not yet recruiting